253 related articles for article (PubMed ID: 29123100)
1. DNA methylation at enhancers identifies distinct breast cancer lineages.
Fleischer T; Tekpli X; Mathelier A; Wang S; Nebdal D; Dhakal HP; Sahlberg KK; Schlichting E; ; Børresen-Dale AL; Borgen E; Naume B; Eskeland R; Frigessi A; Tost J; Hurtado A; Kristensen VN
Nat Commun; 2017 Nov; 8(1):1379. PubMed ID: 29123100
[TBL] [Abstract][Full Text] [Related]
2. Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function.
Jiang G; Wang X; Sheng D; Zhou L; Liu Y; Xu C; Liu S; Zhang J
Theranostics; 2019; 9(22):6501-6516. PubMed ID: 31588232
[TBL] [Abstract][Full Text] [Related]
3. NR2F2 Orphan Nuclear Receptor is Involved in Estrogen Receptor Alpha-Mediated Transcriptional Regulation in Luminal A Breast Cancer Cells.
Erdős E; Bálint BL
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32168782
[TBL] [Abstract][Full Text] [Related]
4. Crosstalk between microRNA expression and DNA methylation drives the hormone-dependent phenotype of breast cancer.
Aure MR; Fleischer T; Bjørklund S; Ankill J; Castro-Mondragon JA; ; Børresen-Dale AL; Tost J; Sahlberg KK; Mathelier A; Tekpli X; Kristensen VN
Genome Med; 2021 Apr; 13(1):72. PubMed ID: 33926515
[TBL] [Abstract][Full Text] [Related]
5. Inferring regulatory element landscapes and transcription factor networks from cancer methylomes.
Yao L; Shen H; Laird PW; Farnham PJ; Berman BP
Genome Biol; 2015 May; 16(1):105. PubMed ID: 25994056
[TBL] [Abstract][Full Text] [Related]
6. Identification of activated enhancers and linked transcription factors in breast, prostate, and kidney tumors by tracing enhancer networks using epigenetic traits.
Rhie SK; Guo Y; Tak YG; Yao L; Shen H; Coetzee GA; Laird PW; Farnham PJ
Epigenetics Chromatin; 2016; 9():50. PubMed ID: 27833659
[TBL] [Abstract][Full Text] [Related]
7. Nonlinear relationship between chromatin accessibility and estradiol-regulated gene expression.
Chen D; Parker TM; Bhat-Nakshatri P; Chu X; Liu Y; Wang Y; Nakshatri H
Oncogene; 2021 Feb; 40(7):1332-1346. PubMed ID: 33420376
[TBL] [Abstract][Full Text] [Related]
8. A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor α-dependent transcriptional activation and breast carcinogenesis.
Peng BL; Li WJ; Ding JC; He YH; Ran T; Xie BL; Wang ZR; Shen HF; Xiao RQ; Gao WW; Ye TY; Gao X; Liu W
Theranostics; 2020; 10(8):3451-3473. PubMed ID: 32206101
[TBL] [Abstract][Full Text] [Related]
9. Effect of estrogen receptor α binding on functional DNA methylation in breast cancer.
Ung M; Ma X; Johnson KC; Christensen BC; Cheng C
Epigenetics; 2014 Apr; 9(4):523-32. PubMed ID: 24434785
[TBL] [Abstract][Full Text] [Related]
10. Global analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with ERalpha.
Frietze S; O'Geen H; Littlepage LE; Simion C; Sweeney CA; Farnham PJ; Krig SR
BMC Genomics; 2014 Jun; 15(1):520. PubMed ID: 24962896
[TBL] [Abstract][Full Text] [Related]
11. FOXA1 Directs H3K4 Monomethylation at Enhancers via Recruitment of the Methyltransferase MLL3.
Jozwik KM; Chernukhin I; Serandour AA; Nagarajan S; Carroll JS
Cell Rep; 2016 Dec; 17(10):2715-2723. PubMed ID: 27926873
[TBL] [Abstract][Full Text] [Related]
12. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
[No Abstract] [Full Text] [Related]
13. A transcriptional complex composed of ER(α), GATA3, FOXA1 and ELL3 regulates IL-20 expression in breast cancer cells.
Lee JY; Park YJ; Oh N; Kwack KB; Park KS
Oncotarget; 2017 Jun; 8(26):42752-42760. PubMed ID: 28514748
[TBL] [Abstract][Full Text] [Related]
14. FOXA1 in breast cancer.
Nakshatri H; Badve S
Expert Rev Mol Med; 2009 Mar; 11():e8. PubMed ID: 19261198
[TBL] [Abstract][Full Text] [Related]
15. Enrichment of CpG island shore region hypermethylation in epigenetic breast field cancerization.
Muse ME; Titus AJ; Salas LA; Wilkins OM; Mullen C; Gregory KJ; Schneider SS; Crisi GM; Jawale RM; Otis CN; Christensen BC; Arcaro KF
Epigenetics; 2020 Oct; 15(10):1093-1106. PubMed ID: 32255732
[TBL] [Abstract][Full Text] [Related]
16. Breast tumor specific mutation in GATA3 affects physiological mechanisms regulating transcription factor turnover.
Adomas AB; Grimm SA; Malone C; Takaku M; Sims JK; Wade PA
BMC Cancer; 2014 Apr; 14():278. PubMed ID: 24758297
[TBL] [Abstract][Full Text] [Related]
17. Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility.
Wen W; Chen Z; Bao J; Long Q; Shu XO; Zheng W; Guo X
Nat Commun; 2021 Sep; 12(1):5318. PubMed ID: 34518541
[TBL] [Abstract][Full Text] [Related]
18. TNFα signaling exposes latent estrogen receptor binding sites to alter the breast cancer cell transcriptome.
Franco HL; Nagari A; Kraus WL
Mol Cell; 2015 Apr; 58(1):21-34. PubMed ID: 25752574
[TBL] [Abstract][Full Text] [Related]
19. TET2 is a component of the estrogen receptor complex and controls 5mC to 5hmC conversion at estrogen receptor cis-regulatory regions.
Broome R; Chernukhin I; Jamieson S; Kishore K; Papachristou EK; Mao SQ; Tejedo CG; Mahtey A; Theodorou V; Groen AJ; D'Santos C; Balasubramanian S; Farcas AM; Siersbæk R; Carroll JS
Cell Rep; 2021 Feb; 34(8):108776. PubMed ID: 33626359
[TBL] [Abstract][Full Text] [Related]
20. Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.
Droog M; Nevedomskaya E; Kim Y; Severson T; Flach KD; Opdam M; Schuurman K; Gradowska P; Hauptmann M; Dackus G; Hollema H; Mourits M; Nederlof P; van Boven H; Linn SC; Wessels L; van Leeuwen FE; Zwart W
Cancer Res; 2016 Jul; 76(13):3773-84. PubMed ID: 27197147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
